ReviewBladder cancer (Amsterdam, Netherlands)2018
Antibody-Drug Conjugates in Bladder Cancer.
Review in Bladder cancer (Amsterdam, Netherlands), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development.Cancers · 2024Review
- Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Transurethral resection of bladder tumor-based bladder preservation therapy for refractory high risk non-muscle invasive bladder cancer: Current landscape and future directions.Frontiers in surgery · 2023Article
- Treatment and disease management patterns for bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer in North America, Europe and Asia: A real-world data analysis.Current urology · 2022Article
- A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.Investigative and clinical urology · 2022Review
- Review
- Development of Novel Aptamer-Based Targeted Chemotherapy for Bladder Cancer.Cancer research · 2022Article
- The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics.Leukemia research reports · 2022Article
- Biomaterials from the sea: Future building blocks for biomedical applications.Bioactive materials · 2021Review
- Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications.Molecular therapy oncolytics · 2021Review
- Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective.Antibodies (Basel, Switzerland) · 2021Review
- The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer.Journal of managed care & specialty pharmacy · 2021Article
- Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics.Frontiers in oncology · 2021Review
- Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic.Pharmaceutics · 2020Article
- Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?International journal of molecular sciences · 2020Review
- Precision oncology in urothelial cancer.ESMO open · 2020Review
- Novel Combination Therapies for the Treatment of Bladder Cancer.Frontiers in oncology · 2020Review
- Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer ("KEYNOTE 045").Translational andrology and urology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urothelial carcinoma (UC) is characterized by expression of a plethora of cell surface antigens, thus offering opportunities for specific therapeutic targeting with use of antibody-drug conjugates (ADCs). ADCs are structured from two major constituents, a monoclonal antibody (mAb) against a specific target and a cytotoxic drug connected via a linker molecule. Several ADCs are developed against different UC surface markers, but the ones at most advanced stages of development include sacituzumab govitecan (IMMU-132), enfortumab vedotin (ASG-22CE/ASG-22ME), ASG-15ME for advanced UC, and oportuzumab monatox (VB4-845) for early UC. Several new targets are identified and utilized for novel or existing ADC testing. The most promising ones include human epidermal growth factor receptor 2 (HER2) and members of the fibroblast growth factor receptor axis (FGF/FGFR). Positive preclinical and early clinical results are reported in many cases, thus the next step involves further improving efficacy and reducing toxicity as well as testing combination strategies with approved agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.